The CSL Limited (ASX: CSL) share price could be on the rise on Wednesday after being the subject of a positive broker note out of Goldman Sachs.
What did Goldman Sachs say?
According to the note, Goldman Sachs has been looking through the biotherapeutics company’s R&D pipeline.
It has explored each of the 15 projects that are in or near active development. And, after assessing the data and likely regulatory pathway, the broker calculates a total risk-adjusted valuation of A$38 per share.
This leads to an increase in its price target to $312.00, which implies potential upside of 12% over the next 12 months. Goldman Sachs retains its buy rating.
Which products is Goldman bullish on?
Goldman is very positive on its clazakizumab, CSL842 and CSL964 products.
The broker said: “We believe the most compelling opportunities under development are within the Transplant franchise (clazakizumab, CSL842 and CSL964), for which we assign a total risk-adjusted valuation of A$24 per share (62% of total).”
Its analysts also note that CSL312 and CSL311 have a lot of promise.
“The factor XIIa antagonist is interesting (CSL312), as a potential flagship in HAE in the first instance, but later with possible applications in various coagulation indications, which could provide upside to our current valuation of A$3.3.”
“Longer-term, the Fc multimer holds clear promise in various auto-immune indications and the push into respiratory markets with CSL311 could make sense (severe asthma, nasal polyposis, COPD),” the broker added.
Should you invest?
I agree with Goldman Sachs that CSL is a buy and believe it is well-positioned to deliver solid earnings growth over the next decade.
This is thanks to the aforementioned development pipeline, its growing plasma collection network, and the increasing demand for immunoglobulins.
Incidentally, in another note, Goldman slapped a neutral rating on Altium Limited (ASX: ALU) shares. It has a $33.55 price target on the design software provider’s shares.
The post Leading broker tips CSL share price to hit $312 appeared first on Motley Fool Australia.
And here are five more shares that have been given buy ratings along with CSL.
Our Motley Fool experts have just released a brand new FREE report, detailing 5 dirt cheap shares that you can buy today.
One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…
Another is a diversified conglomerate trading near a 52-week low all while offering a 2.8% fully franked yield...
Plus 3 more cheap bets that could position you to profit over the next 12 months!
See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.
- Man bets $221,666 on one ASX stock
- Top analysts name their top 3 ASX blue chip shares for 2019
- 3 quality dividend shares to boost your income
- NEW: Free report names top 3 ASX dividend shares to buy for 2019
- 5 Stocks for Potentially Building Wealth After 50
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia owns shares of Altium. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2019